Spontaneous clearance of the human papilloma virus as a result of suppressive therapy with acyclic nucleosides of a recurrent herpes-viral infection


Cite item

Full Text

Abstract

Background. Genital human papillomavirus (HPV) infection is not effectively controlled and treated. Current dates suggest that 80% cases of HPV infections are transient and clear spontaneously, it is connected with the deterministic immune response. Results of several independent studies suggest that HSV-2 infections correlate with a higher than normal incidence of cervical cancer. Objectives. This study demonstrated a spontaneous clearance of the HPV follow the suppressive therapy of a recurrent HSV infection with acyclic nucleosides. Study design. We carried out a parallel observational study from 2015 to 2017. Herpes suppressive therapy with acyclic nucleosides (valacyclovir of 500 mg per day) during a 6 months is used to treat patients (n=32) aged 28 to 34 years (mean age 30.4±2.1 years) who have recurrent genital HSV infection and HPV infection both. The detection of HPV by RT-PCR before and after ant-herpetic therapy was investigated. Results. After treatment of HSV infection eradication of the one types of HPV was achieved in 43.75% cases, eradication of HPV-16 was achieved only in 15.4% (in 2 out of 13 patients) of cases, eradication HPV-18 was achieved in 25% (in 4 out of 16 patients) of cases. Decreasing of viral load occurred in 62.5% patients, full HPV-clearance was recorded in 15.6% of patients, but the high viral-load of HPV infection was preserved in 37.5% of the cases.

About the authors

N I Tapilskaya

Saint Petersburg Pediatric University of the Ministry of Health of the Russian Federation

Email: tapnatalia@yandex.ru
д-р мед. наук, проф., проф. каф. акушерства и гинекологии (с курсом гинекологии детского и подросткового возраста), проф. каф. онкологии, детской онкологии и лучевой терапии ФГБОУ ВО СПбГПМУ 194100, Russian Federation, Saint Petersburg, ul. Litovskaia, d. 2

I N Vorobtsova

Saint Petersburg Pediatric University of the Ministry of Health of the Russian Federation

канд. мед. наук, доц. каф. акушерства и гинекологии (с курсом гинекологии детского и подросткового возраста) ФГБОУ ВО СПбГПМУ 194100, Russian Federation, Saint Petersburg, ul. Litovskaia, d. 2

R I Glushakov

S.M.Kirov Medical Military Academy of the Ministry of Defence of the Russian Federation

канд. мед. наук, и. о. зав. отд-нием вспомогательных репродуктивных технологий клиники акушерства и гинекологии ФГБВОУ ВО «ВМА им. С.М.Кирова» 194044, Russian Federation, Saint Petersburg, ul. Akademika Lebedeva, d. 6

References

  1. Van Der Pol B. Sexually transmitted infections in women. Scand J Clin Lab Invest Suppl 2014; 74 (244): 68-74.
  2. Тапильская Н.И., Воробцова И.Н., Гайдуков С.Н., Прошин С.Н. Оценка эффективности и безопасности применения имихимода в лечении субклинических и клинических проявлений персистирующей папилломавирусной инфекции шейки матки у пациенток раннего репродуктивного возраста // Гинекология. 2015; 17 (1): 14-7.
  3. Rawls W, Tompkins W, Figueroa M, Melnick J. Herpesvirus type 2: association with carcinoma of the cervix. Science (New York, NY) 1968; 161 (847): 1255.
  4. Hausen H. Human genital cancer: synergism between two virus infections or synergism between a virus infection and initiating events? Lancet 1982; 320 (8312): 1370-2.
  5. Vonka V, Kanka J, Hirsch I et al. Prospective study on the relationship between cervical neoplasia and herpes simplex type-2 virus. II. Herpes simplex type-2 antibody presence in sera taken at enrollment. Int J Cancer 1984; 33 (1): 61-6.
  6. Lehtinen M, Koskela P, Jellum E et al. Herpes simplex virus and risk of cervical cancer: a longitudinal, nested case - control study in the Nordic countries. Am J Epidemiol 2002: 156 (8): 687-92.
  7. Cao S, Gan Y, Dong X, Lu Z. Herpes simplex virus type 2 and the risk of cervical cancer: a meta - analysis of observational studies. Arch Gynecol Obstet 2014; 290: 1059-66. doi: 10.1007/s00404-014-3365-7
  8. Smith J.S, Herrero R, Bosetti C et al. Herpes simplex virus-2 as a human papillomavirus cofactor in the etiology of invasive cervical cancer. J Natl Cancer Inst 2002; 94: 1604-13.
  9. Hoffmann M, Quabius E.S, Tribius S et al. Human papillomavirus infection in head and neck cancer: the role of the secretory leukocyte protease inhibitor. Oncol Rep 2013; 29: 1962-8.
  10. Генитальный герпес. Под ред. А.А.Кубановой. Клинические рекомендации. Российское общество дерматовенерологов. М.: ДЭКС-Пресс, 2010.
  11. Hibma M.H. The immune response to papillomavirus during infection persistence and regression. Open Virol J 2012; 6: 241-8. doi: 10.2174/1874357901206010241
  12. Amador-Molina A, Hernández-Valencia J.F, Lamoyi E et al. Role of innate immunity against human papillomavirus (HPV) infections and effect of adjuvants in promoting specific immune response. Viruses 2013; 5 (11): 2624-42. doi: 10.3390/v5112624
  13. Прошин С.Н., Глушаков Р.И., Шабанов П.Д. и др. Значение экспрессии TLR-рецепторов для выбора фармакологической коррекции патологии шейки матки и эндометрия. Гены и клетки. 2011; 6 (1): 91-7.
  14. Wahid B, Ali A, Idrees M, Rafique S. Immunotherapeutic strategies for sexually transmitted viral infections: HIV, HSV and HPV. Cell Immunol 2016; 310: 1-13. doi: 10.1016/j.cellimm.2016.08.001
  15. Jemon K, Leong C.M, Ly K et al. Suppression of the CD8+ T cell response by human papillomavirus type 16 E7 occurs in Langerhans cell - depleted mice. Sci Rep 2016; 6: 34789. doi: 10.1038/srep34789
  16. Guidry J.T, Scott R.S. The interaction between human papillomavirus and other viruses. Virus Res 2017; 231: 139-47. doi: 10.1016/j.virusres.2016.11.002
  17. Joseph G Skeate, Tania B et al. Herpes simplex virus downregulation of secretory leukocyte protease inhibitor enhances human papillomavirus type 16 infection. J Gen Virol 2016; 97: 422-34. doi: 10.1099/jgv.0.000341
  18. Woodham A.W, Raff A.B, Raff L.M et al. Inhibition of Langerhans cell maturation by human papillomavirus type 16: a novel role for the annexin A2 heterotetramer in immune suppression. J Immunol 2014: 192: 4748-57.
  19. Mesquita P.M.M, Preston-Hurlburt P, Keller M.J et al. Role of Interleukin 32 in Human Immunodeficiency Virus Reactivation and Its Link to Human Immunodeficiency Virus-Herpes Simplex Virus Coinfection. J Infect Dis 2017; 215 (4): 614-22. DOI: https://doi.org/10.1093/infdis/jiw612
  20. Huang H.S, Lambert P.F. Use of an in vivo animal model for assessing the role of integrin a6b4 and syndecan-1 in early steps in papillomavirus infection. Virology. 2012; 433: 395-400.
  21. Cermelli C, Orsi C.F, Ardizzoni A et al. Herpes simplex virus type 1 dysregulates antifungal defenses preventing monocyte activation and downregulating toll - like receptor-2. Microbiol Immunol 2008; 52 (12): 575-84.
  22. Shannon B, Gajer P, Yi TJ et al. Distinct effects of the cervicovaginal microbiota and herpes simplex type 2 infection on female genital tract immunology. J Infect Dis 2017; 215 (9): 1366-75. DOI: https://doi.org/10.1093/infdis/jix088
  23. Plotkin B.J, Sigar I.M, Tiwari V, Halkyard S. Herpes simplex virus (HSV) modulation of Staphylococcus aureus and Candida albicans initiation of HeLa 299 cell - associated biofilm. Curr Microbiol 2016; 72: 529-37. doi: 10.1007/s00284-015-0975-7
  24. Satapathy S, Batra J, Jeet V et al. MicroRNAs in HPV associated cancers: small players with big consequences. Expert Rev Mol Diagn 2017; 17 (7): 711-22. doi: 10.1080/14737159.2017.1339603
  25. Косарев В.В., Бабанов С.А. Клиническая фармакология и рациональная фармакотерапия. М.: Вузовский учебник; ИНФРА-М, 2012.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2017 Consilium Medicum

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

Согласие на обработку персональных данных

 

Используя сайт https://journals.rcsi.science, я (далее – «Пользователь» или «Субъект персональных данных») даю согласие на обработку персональных данных на этом сайте (текст Согласия) и на обработку персональных данных с помощью сервиса «Яндекс.Метрика» (текст Согласия).